RxDoctor Payments Data

Timinder Biring, MD

Cardiovascular Disease · Edina, MNNPI 1487621017

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Medtronic at 29.5% of the total. Reporting peaked in 2022 at $15,866 and has fallen 54.5% since, to $7,215 in 2025.

$43,472in general payments, 2019–2025

Across 175 payments — averaging $248.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$13K
  • Boston Scientific$11K
  • Shockwave Medical, Inc$8K
  • Cordis US CORP.$5K
  • Arrow International, Inc.$4K
  • Teleflex LLC$2K
  • plus $701 from 6 others
$65,056in research payments, 2019–2025

Across 22 payments — averaging $2957.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cardiovascular Systems Inc.$54K
  • Medtronic$11K
  • Teleflex LLC$300

What the payments were for

  • Consulting fees$24,18856%
  • Speaking & faculty fees$3,8509%
  • Travel & lodging$10,14123%
  • Food & beverage$5,28212%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,472 in reported general payments places this provider in the 85th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota →

Medicare billing

Part B allowed, 2024
$80,317
Medicare patients
307
Services billed
724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$133,762
Repatha SureclickEvolocumab33$44,333
BrilintaTicagrelor38$30,451
EntrestoSacubitril/Valsartan13$22,165
XareltoRivaroxaban25$22,067
Metoprolol Succinate179$3,238
Atorvastatin Calcium160$2,307
Carvedilol99$1,426
Amlodipine Besylate126$1,406
Lisinopril118$955
Rosuvastatin Calcium70$939
Metoprolol Tartrate81$778
Losartan Potassium62$752
Isosorbide Mononitrate ErIsosorbide Mononitrate34$627
Torsemide12$390

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Edina

See the full list for Minnesota →

Where these figures come from

Is this you, or does something look wrong? →